Zemba Mihail, Radu Madalina, Istrate Sinziana, Dumitrescu Otilia-Maria, Ionescu Mihai Alexandru, Vatafu Andrei, Barac Ileana Ramona
Department of Ophthalmology, University of Medicine and Pharmacy "Carol Davila", 050474 Bucharest, Romania.
Department of Ophthalmology, "Dr. Carol Davila" Central Military Emergency University Hospital, 010825 Bucharest, Romania.
Pharmaceutics. 2023 Mar 29;15(4):1091. doi: 10.3390/pharmaceutics15041091.
Infectious keratitis is a major global cause of vision loss and blindness. Prompt diagnosis and targeted antibiotic treatment are crucial for managing the condition. Topical antimicrobials are the most effective therapy for bacterial keratitis, but they can lead to unsatisfactory results due to ocular perforation, scarring, and melting. Intrastromal injection is a newer technique for delivering antimicrobials directly to the site of infection and has been successful in treating severe, treatment-resistant infectious keratitis, especially when surgery is not recommended. In cases where deep stromal disease is resistant to topical treatment, intrastromal antimicrobial injections may be necessary to achieve higher drug concentration at the infection site. However, the use of intrastromal antibiotics is limited, as topical antibacterial agents have better penetration than antifungal agents. Bacterial and fungal keratitis have been extensively researched for intrastromal medication injections, while there is limited evidence for viral keratitis. This review emphasizes the potential of intrastromal antimicrobial injections as an alternative for managing severe refractory infectious keratitis. The technique offers direct targeting of the infection site and faster resolution in some cases compared to topical therapy. However, further research is needed to determine the safest antimicrobials options, minimal effective doses, and concentrations for various pathogens. Intrastromal injections may serve as a non-surgical treatment option in high-risk cases, with benefits including direct drug delivery and reduced epithelial toxicity. Despite promising findings, more studies are required to confirm the safety and efficacy of this approach.
感染性角膜炎是全球视力丧失和失明的主要原因。及时诊断和针对性的抗生素治疗对于控制病情至关重要。局部使用抗菌药物是治疗细菌性角膜炎最有效的方法,但由于角膜穿孔、瘢痕形成和角膜溶解,可能导致治疗效果不理想。基质内注射是一种将抗菌药物直接输送到感染部位的新技术,已成功用于治疗严重的、耐药性感染性角膜炎,特别是在不建议进行手术的情况下。在深层基质疾病对局部治疗耐药的情况下,可能需要进行基质内抗菌药物注射,以在感染部位达到更高的药物浓度。然而,基质内抗生素的使用受到限制,因为局部抗菌药物的穿透性优于抗真菌药物。对于基质内药物注射治疗细菌性和真菌性角膜炎已有广泛研究,而关于病毒性角膜炎的证据有限。本综述强调了基质内抗菌药物注射作为治疗严重难治性感染性角膜炎替代方法的潜力。与局部治疗相比,该技术可直接针对感染部位,在某些情况下能更快地解决问题。然而,需要进一步研究以确定针对各种病原体的最安全抗菌药物选择、最小有效剂量和浓度。基质内注射可作为高危病例的非手术治疗选择,其优点包括直接给药和降低上皮毒性。尽管有令人鼓舞的发现,但仍需要更多研究来证实这种方法的安全性和有效性。